Obesity as a Multidisciplinary Challenge
DOI:
https://doi.org/10.12775/QS.2026.49.66725Keywords
Obesity, Diet, Anti-obesity drugs, Psychotherapy, Bariatric SurgeryAbstract
Purpose. Obesity is a chronic metabolic disease that has reached epidemic proportions worldwide, affecting individuals across all ages, genders, and socioeconomic backgrounds. Its growing prevalence presents a significant public health issue due to the various complications it leads to, such as metabolic disorders, cardiovascular diseases, and psychological or social problems. The aim of this article is to analyze the effectiveness of current therapeutic approaches to obesity, with particular focus on dietary interventions, pharmacotherapy, psychotherapy, and surgical treatment.
Materials and Methods. This article is based on a literature review of obesity treatment methods. Data from clinical trials, meta-analyses, and clinical guidelines were selected through searches in databases such as PubMed and Google Scholar. Keywords are “obesity”, “diet”, “anti-obesity drugs”, “pharmacotherapy”, “psychotherapy” and “bariatric surgery.” Priority was given to studies published between 2020 and 2025.
Findings. This review provides an overview of current obesity treatment strategies. While dietary changes are the key element of treatment, combining them with pharmacotherapy and psychological support enhances effectiveness and leads to better long-term outcomes. Surgical intervention is reserved for severe cases after other methods have been explored. Each approach is assessed for its effectiveness, safety, and role within a comprehensive treatment plan.
References
1. Busebee, B., Ghusn, W., Cifuentes, L., & Acosta, A. (2023). Obesity: A review of pathophysiology and classification. Mayo Clinic Proceedings, 98(12), 1842–1857. https://doi.org/10.1016/j.mayocp.2023.05.026
2. World Health Organization. (2025, May). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
3. Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., et al. (2023). Pathophysiology of obesity and its associated diseases. Acta Pharmaceutica Sinica B, 13(6), 2403–2424. https://doi.org/10.1016/j.apsb.2023.01.012
4. Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009). The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health, 9, 88. https://doi.org/10.1186/1471-2458-9-88
5. Clifton, P. M. (2008). Dietary treatment for obesity. Nature Clinical Practice Gastroenterology & Hepatology, 5(12), 672–681. https://doi.org/10.1038/ncpgasthep1283
6. Avenell, A., Broom, J., Brown, T. J., Poobalan, A., Aucott, L., Stearns, S. C., et al. (2004). What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. Journal of Human Nutrition and Dietetics, 17(4), 317–335. https://doi.org/10.1111/j.1365-277X.2004.00520.x
7. Di Rosa, C., Lattanzi, G., Spiezia, C., Imperia, E., Piccirilli, S., Beato, I., et al. (2022). Mediterranean diet versus very low-calorie ketogenic diet: Effects of reaching 5% body weight loss on body composition in subjects with overweight and with obesity—A cohort study. International Journal of Environmental Research and Public Health, 19(20), 13040. https://doi.org/10.3390/ijerph192013040
8. Bąk-Sosnowska, M., Białkowska, M., Bogdański, P., Chomiuk, T., Dobrowolski, P., Gałązka-Sobotka, M., et al. (2024). Zalecenia kliniczne dotyczące postępowania u chorych na otyłość 2024 – stanowisko Polskiego Towarzystwa Leczenia Otyłości. Medycyna Praktyczna. Wydanie Specjalne, 70–91.
9. Hamer, O., Kuroski, J. A., Bray, E. P., Harris, C., Blundell, A., Schneider, E., et al. (2024). Psychological interventions for weight reduction and sustained weight reduction in adults with overweight and obesity: A scoping review. BMJ Open, 14(12), e082973. https://doi.org/10.1136/bmjopen-2023-082973
10. Dalle Grave, R., Sartirana, M., & Calugi, S. (2020). Personalized cognitive-behavioural therapy for obesity (CBT-OB): Theory, strategies and procedures. Biopsychosocial Medicine, 14, 5. https://doi.org/10.1186/s13030-020-00177-9
11. Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022). Wegovy (semaglutide): A new weight loss drug for chronic weight management. Journal of Investigative Medicine, 70(1), 5–13. https://doi.org/10.1136/jim-2021-001952
12. Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y
13. Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2024). Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: A systematic review and meta-analysis of randomized controlled trials. International Journal of Clinical Pharmacy, 46(6), 1268–1280. https://doi.org/10.1007/s11096-024-01779-x
14. Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W. Y., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
15. Rodriguez, P. J., Goodwin Cartwright, B. M., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., et al. (2024). Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Internal Medicine, 184(9), 1056–1064. https://doi.org/10.1001/jamainternmed.2024.2525
16. Aaseth, J., Ellefsen, S., Alehagen, U., Sundfør, T. M., & Alexander, J. (2021). Diets and drugs for weight loss and health in obesity – An update. Biomedicine & Pharmacotherapy, 140, 111789. https://doi.org/10.1016/j.biopha.2021.111789
17. Lyu, Y. S., Ahn, H., Hong, S., & Park, C. Y. (2024). Safety and effectiveness of naltrexone-bupropion in Korean adults with obesity: Post-marketing surveillance study. Drug Design, Development and Therapy, 18, 5255–5268. https://doi.org/10.2147/DDDT.S492913
18. Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., et al. (2013). A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring), 21(5), 935–943. https://doi.org/10.1002/oby.20309
19. Jain, S. S., Ramanand, S. J., Ramanand, J. B., Akat, P. B., Patwardhan, M. H., & Joshi, S. R. (2011). Evaluation of efficacy and safety of orlistat in obese patients. Indian Journal of Endocrinology and Metabolism, 15(2), 99–104. https://doi.org/10.4103/2230-8210.81938
20. Zhu, J., Hu, M., Liang, Y., Zhong, M., Chen, Z., Wang, Z., et al. (2024). Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database. Heliyon, 10(14), e34837. https://doi.org/10.1016/j.heliyon.2024.e34837
21. Peirson, L., Douketis, J., Ciliska, D., Fitzpatrick-Lewis, D., Ali, M. U., & Raina, P. (2014). Treatment for overweight and obesity in adult populations: A systematic review and meta-analysis. CMAJ Open, 2(4), E306–E317. https://doi.org/10.9778/cmajo.20140012
22. Elder, K. A., & Wolfe, B. M. (2007). Bariatric surgery: A review of procedures and outcomes. Gastroenterology, 132(6), 2253–2271. https://doi.org/10.1053/j.gastro.2007.03.057
23. Ram Sohan, P., Mahakalkar, C., Kshirsagar, S., Bikkumalla, S., Reddy, S., Hatewar, A., et al. (2024). Long
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Aleksandra Mazur, Krzysztof Sajewicz, Julia Dulęba, Paulina Strzałkowska , Filip Kin, Joanna Koszałko , Monika Kaźmierczak, Maciej Hobot, Julia Kalisiak, Nel Geworkian
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 29
Number of citations: 0
